From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency ...

For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing public health issue of obesity in America" and ties in with the company's ...

Newel Health has been granted EU medical device certification for its virtual reality-based digital therapeutic (DTx) for chronic pain, clearing the way for a launch in Europe.

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

2024 was pivotal for UK Life Sciences’ venture funding landscape. Softening macro and geopolitical conditions saw activity ...